Menu
Search
|

Menu

Close
X

Advaxis Inc ADXS.OQ (NASDAQ Stock Exchange Global Select Market)

2.51 USD
-0.13 (-4.92%)
As of Feb 17
chart
Previous Close 2.64
Open 2.63
Volume 136,399
3m Avg Volume 191,134
Today’s High 2.72
Today’s Low 2.50
52 Week High 10.05
52 Week Low 2.44
Shares Outstanding (mil) 41.07
Market Capitalization (mil) 187.67
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.50 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY17
12
FY16
4
FY15
0
EPS (USD)
FY17
-2.302
FY16
-2.074
FY15
-1.667
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
13.39
5.77
Price to Book (MRQ)
vs sector
2.52
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
0.00
16.52
LT Debt to Equity (MRQ)
vs sector
0.00
12.22
Return on Investment (TTM)
vs sector
-105.74
14.43
Return on Equity (TTM)
vs sector
-116.33
16.13

EXECUTIVE LEADERSHIP

David Sidransky
Independent chairman of the Board of Director, Since 2015
Salary: $97,750.00
Bonus: $204,000.00
Anthony Lombardo
Interim Chief Executive Officer, Since 2017
Salary: --
Bonus: --
James Patton
Non-Executive Independent Vice Chairman of the Board, Since 2015
Salary: --
Bonus: --
Sara Bonstein
Chief Financial Officer, Executive Vice President, Since 2016
Salary: $338,931.00
Bonus: $671,000.00
Robert Petit
Executive Vice President, Chief Scientific Officer, Since 2013
Salary: $337,689.00
Bonus: $930,000.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

305 College Rd E
PRINCETON   NJ   08540-6608

Phone: +1732.5451590

Advaxis, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-LLO strains integrate multiple functions into a single immunotherapy as they access and direct antigen presenting cells to stimulate anti-tumor T-cell immunity, stimulate and activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable the T-cells to eliminate tumors. Axalimogene filolisbac is its lead Lm-LLO immunotherapy product candidate for the treatment of Human Papilloma Virus-associated cancers. ADXS-PSA is its Lm-LLO immunotherapy product candidate that targets the Prostate Specific Antigen (PSA) associated with prostate cancer.

SPONSORED STORIES